Download Sample
Add to CartHormonal Implants Market
By Hormone;
Levonorgestrel and EtonogestrelBy Type;
One Rod Device and Two Rod DeviceBy Distribution Sector;
Public Sector and Private SectorBy End User;
Hospitals & Clinics and Academic & Research InstitutesBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Introduction
Global Hormonal Implants Market (USD Million), 2021 - 2031
In the year 2024, the Global Hormonal Implants Market was valued at USD 1165.95 million. The size of this market is expected to increase to USD 1872.26 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.0%.
Hormonal Implants Market
*Market size in USD million
CAGR 7.0 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 7.0 % |
| Market Size (2024) | USD 1165.95 Million |
| Market Size (2031) | USD 1872.26 Million |
| Market Concentration | Medium |
| Report Pages | 322 |
Major Players
- Merck & Co., Inc.
- Bayer AG
- Allergan plc (now part of AbbVie Inc.)
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V. (now part of Viatris Inc.)
- BioSante Pharmaceuticals, Inc.
- Radius Health, Inc.
- Agile Therapeutics, Inc.
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Hormonal Implants Market
Fragmented - Highly competitive market without dominant players
The global hormonal implants market has been experiencing notable growth, driven by several factors including rising prevalence of hormonal disorders, increasing awareness about long-acting contraceptive methods, and advancements in implant technology. Hormonal implants offer a convenient and effective solution for managing various hormonal conditions such as contraception, hormone replacement therapy, and hormonal disorders like hypogonadism. The growing demand for long-acting reversible contraceptives (LARCs) due to their high efficacy, convenience, and cost-effectiveness has significantly contributed to the expansion of the hormonal implants market.
Key players in the global hormonal implants market are investing in research and development activities to introduce innovative products and expand their market presence. Technological advancements such as the development of biodegradable implants and improvements in drug delivery systems are driving market growth by enhancing the safety, efficacy, and patient comfort associated with hormonal implants. Additionally, strategic collaborations, partnerships, and acquisitions are enabling companies to strengthen their product portfolios and expand into new geographic regions, further fueling market growth.
However, the market faces challenges such as stringent regulatory requirements, concerns regarding side effects associated with hormonal therapy, and competition from alternative contraceptive methods. Moreover, limited access to healthcare facilities, particularly in developing regions, may hinder market growth to some extent. Nonetheless, increasing healthcare expenditure, growing emphasis on family planning initiatives, and rising adoption of hormonal implants as a preferred choice for contraception and hormone therapy are expected to create lucrative opportunities for market players in the coming years.
Global Hormonal Implants Market Recent Developments
-
In 30th March 2024, it was reported that Canada will cover the full cost of contraception for women as announced by the government and highlighted the first part of a major health care reform.
-
In May 2016, ALLERGAN took an initiative to help the US military servicewomen access LILETTA at a Federal Supply Schedule (FSS) price of USD 55.83 to military treatment facilities nationwide. The initiative also includes an educational effort to raise contraception awareness among healthcare providers treating the US military servicewomen.
Hormonal Implants Market Segment Analysis
In this report, the Hormonal Implants Market has been segmented by Hormone, Type, Distribution Sector, End User, and Geography.
Hormonal Implants Market, Segmentation by Hormone
The Hormonal Implants Market has been segmented by Hormone into Levonorgestrel and Etonogestrel.
Levonorgestrel
Levonorgestrel implants dominate the hormonal implants market, representing nearly 60% of global usage. Celebrated for their long-term contraceptive benefits, these implants offer protection for 3–5 years with a success rate exceeding 99%. Women increasingly prefer levonorgestrel due to its ease of insertion, reliability, and reversibility. Market growth is fueled by rising awareness, accessibility in emerging economies, and confidence in its proven effectiveness.
Etonogestrel
Etonogestrel-based implants contribute roughly 35–40% of the hormonal implants market. They are recognized for consistent hormone delivery and high contraceptive efficacy, lasting up to 3 years. The implants are associated with minimal side effects, making them a preferred choice among users seeking comfort and convenience. Expansion of reproductive health education and improved clinic accessibility continue to support rising global adoption, with user satisfaction rates exceeding 95%.
Hormonal Implants Market, Segmentation by Type
The Hormonal Implants Market has been segmented by Type into One Rod Device and Two Rod Device.
One Rod Device
One rod hormonal implants dominate the market with about 55–60% share, thanks to their simplicity and ease of use. These implants provide up to 3 years of reliable contraception and are favored for minimal procedural complications and enhanced user comfort. Expansion of healthcare awareness and improved availability in clinics and pharmacies continues to drive global adoption.
Two Rod Device
Two rod hormonal implants hold roughly 35–40% of the market and are valued for their controlled hormone release over 3–5 years. While insertion requires slightly more expertise, the implants maintain high efficacy rates exceeding 99%. Increasing adoption in developed regions and growing reproductive health programs are key factors supporting market growth worldwide.
Hormonal Implants Market, Segmentation by Distribution Sector
The Hormonal Implants Market has been segmented by Distribution Sector into Public Sector and Private Sector.
Public Sector
Public sector distribution dominates the hormonal implants market with nearly 50–55% share, driven by government-funded programs that ensure affordable access. These initiatives improve accessibility in rural areas and low-income communities, and are supported by national family planning campaigns. Public health awareness and community outreach continue to boost adoption of hormonal contraceptive implants.
Private Sector
Private sector distribution accounts for about 45–50% of the market, providing quick access, personalized services, and a variety of implant options. Urban populations and rising disposable incomes are fueling the demand for private clinics and pharmacies. Enhanced customer service, counseling, and follow-up support make the private sector a preferred choice for many women seeking hormonal implants.
Hormonal Implants Market, Segmentation by End User
The Hormonal Implants Market has been segmented by End User into Hospitals & Clinics and Academic & Research Institutes.
Hospitals & Clinics
Hospitals and clinics represent the largest end-user segment, with around 70–75% share of hormonal implant distribution. These facilities provide trained medical staff, safe insertion procedures, and effective follow-up care, ensuring high reliability and patient satisfaction. Continuous improvements in healthcare infrastructure and growing patient awareness of contraceptive options are driving market growth.
Academic & Research Institutes
Academic and research institutes account for about 25–30% of the end-user market, focusing on clinical trials, product research, and development of new hormonal implants. Collaborations with pharmaceutical companies and increasing research funding support innovations in contraceptive technology. The segment is pivotal for scientific advancement and evidence-based improvements in hormonal implant solutions.
Hormonal Implants Market, Segmentation by Geography
In this report, the Hormonal Implants Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
Hormonal Implants Market Share (%), by Geographical Region
North America
North America holds approximately 30–35% of the global hormonal implants market, supported by advanced healthcare infrastructure and high awareness of family planning. Urban centers show high adoption of levonorgestrel and etonogestrel implants, with continuous innovation and government initiatives further boosting market growth.
Europe
Europe accounts for about 25–28% of the market, with strong emphasis on safe and effective contraceptive solutions. Countries like Germany, France, and the UK lead in adoption of long-acting reversible contraceptives, fueled by accessible healthcare services and growing awareness of reproductive health.
Asia Pacific
Asia Pacific represents around 20–25% of the hormonal implants market, driven by rising population, improved healthcare access, and active family planning initiatives. India, China, and Japan are key contributors, with government and NGO programs significantly enhancing implant adoption rates.
Middle East and Africa
The Middle East and Africa region captures roughly 10–12% of the global market, with rising demand due to government healthcare programs, NGO initiatives, and increasing awareness. Expanding access to rural healthcare facilities and cultural education campaigns are supporting market growth.
Latin America
Latin America contributes around 8–10% of the market, driven by urban population growth, improved healthcare access, and rising disposable income. Brazil and Mexico are leading markets, benefiting from family planning initiatives and reproductive health campaigns that enhance hormonal implant adoption.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Hormonal Implants Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Rising Prevalence of Hormonal Disorders
- Increasing Demand for Long-Acting Contraceptive Methods
-
Advancements in Implant Technology-Advancements in implant technology are revolutionizing the global hormonal implants market, offering patients and healthcare providers enhanced safety, efficacy, and convenience. Innovations in implant design, such as the development of biodegradable materials and controlled-release systems, have led to implants that provide more precise hormone delivery and improved patient comfort. These technological advancements are addressing previous concerns about implant migration, expulsion, and side effects, thereby boosting confidence in hormonal implants as a viable treatment option for various hormonal disorders and contraceptive needs.
Advancements in implant technology are expanding the applicability of hormonal implants beyond traditional uses, opening up new opportunities in hormone replacement therapy and the treatment of conditions like hypogonadism. Customizable implant designs and drug delivery systems allow for tailored treatment regimens that meet the unique needs of individual patients, enhancing therapeutic outcomes and patient satisfaction. Additionally, improvements in implant insertion techniques and removal procedures are making hormonal implants more accessible and user-friendly, further driving market growth and adoption.
As technology continues to evolve, the future of hormonal implants holds promise for even greater innovation and refinement. Ongoing research and development efforts are focused on enhancing implant biocompatibility, prolonging drug release durations, and minimizing adverse effects. These advancements are expected to drive further market expansion by addressing existing limitations and meeting the evolving demands of patients and healthcare providers for safe, effective, and convenient hormonal implant solutions.
Restraints:
- Stringent Regulatory Requirements
- Concerns about Side Effects
-
Competition from Alternative Contraceptive Methods-Competition from alternative contraceptive methods presents a significant challenge to the global hormonal implants market. While hormonal implants offer long-acting and highly effective contraception, they face competition from a variety of contraceptive options, including oral contraceptives, intrauterine devices (IUDs), and barrier methods such as condoms. These alternatives appeal to individuals seeking different modes of contraception based on factors such as convenience, reversibility, and personal preferences. As a result, the hormonal implants market must navigate a competitive landscape where consumers have diverse options to choose from, each with its own benefits and drawbacks.
One of the key factors contributing to competition from alternative contraceptive methods is the wide availability and accessibility of these options. Oral contraceptives, for example, are widely prescribed and readily available over-the-counter in many countries, offering women a convenient and familiar form of birth control. Similarly, IUDs have gained popularity due to their long-lasting efficacy and convenience, as they do not require daily administration or regular replacement like hormonal implants. Additionally, barrier methods such as condoms offer a non-hormonal alternative that appeals to individuals concerned about hormonal side effects or seeking protection against sexually transmitted infections.
The diversity of contraceptive preferences among consumers further intensifies competition in the hormonal implants market. Some individuals may prefer non-hormonal methods to avoid potential side effects associated with hormonal contraception, while others may prioritize convenience and effectiveness over other factors. Additionally, cultural and societal factors, as well as individual health considerations, play a role in shaping contraceptive choices. As a result, the hormonal implants market must continuously innovate and differentiate its offerings to remain competitive amidst a diverse array of contraceptive options and consumer preferences.
Opportunities:
- Technological Innovations in Implant Design
- Expansion into Emerging Markets
-
Strategic Collaborations and Partnerships-Strategic collaborations and partnerships are playing a pivotal role in shaping the global hormonal implants market, facilitating growth, innovation, and market expansion. Key players in the industry are increasingly leveraging partnerships with other companies, research institutions, and healthcare organizations to drive product development, enhance distribution networks, and strengthen their market presence. By joining forces, companies can combine their expertise, resources, and capabilities to accelerate the development and commercialization of hormonal implant products, ensuring a competitive edge in the market.
Strategic collaborations enable companies to access new markets and expand their geographical footprint. By partnering with local distributors or healthcare providers in emerging economies, manufacturers can overcome barriers to market entry, navigate complex regulatory landscapes, and tailor their marketing strategies to meet the needs of diverse patient populations. These partnerships not only facilitate market penetration but also foster long-term growth opportunities by establishing a strong foothold in high-growth regions with untapped market potential.
Collaborations between industry players and research institutions or academic centers drive innovation and product differentiation. By collaborating on research projects, companies can gain access to cutting-edge technologies, scientific expertise, and clinical insights that inform the development of next-generation hormonal implants. These partnerships facilitate the translation of research findings into practical applications, leading to the development of safer, more effective, and patient-friendly implant solutions. Overall, strategic collaborations and partnerships are instrumental in driving growth, fostering innovation, and addressing unmet needs in the global hormonal implants market.
Competitive Landscape Analysis
Key players in Global Hormonal Implants Market include:
- Merck & Co., Inc.
- Bayer AG
- Allergan plc (now part of AbbVie Inc.)
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V. (now part of Viatris Inc.)
- BioSante Pharmaceuticals, Inc.
- Radius Health, Inc.
- Agile Therapeutics, Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Hormone
- Market Snapshot, By Type
- Market Snapshot, By Distribution Sector
- Market Snapshot, By End User
- Market Snapshot, By Region
- Hormonal Implants Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Rising Prevalence of Hormonal Disorders
- Increasing Demand for Long-Acting Contraceptive Methods
- Advancements in Implant Technology
- Restraints
- Stringent Regulatory Requirements
- Concerns about Side Effects
- Competition from Alternative Contraceptive Methods
- Opportunities
- Technological Innovations in Implant Design
- Expansion into Emerging Markets
- Strategic Collaborations and Partnerships
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Hormonal Implants Market, By Hormone, 2021 - 2031 (USD Million)
- Levonorgestrel
- Etonogestrel
- Hormonal Implants Market, By Type, 2021 - 2031 (USD Million)
- One Rod Device
- Two Rod Device
- Hormonal Implants Market, By Distribution Sector, 2021 - 2031 (USD Million)
- Public Sector
- Private Sector
- Hormonal Implants Market, By End User, 2021 - 2031 (USD Million)
- Hospitals & Clinics
- Academic & Research Institutes
- Hormonal Implants Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Hormonal Implants Market, By Hormone, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Merck & Co., Inc.
- Bayer AG
- Allergan plc (now part of AbbVie Inc.)
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V. (now part of Viatris Inc.)
- BioSante Pharmaceuticals, Inc.
- Radius Health, Inc.
- Agile Therapeutics, Inc.
- Company Profiles
- Analyst Views
- Future Outlook of the Market